Treatment‐related deaths · people with advanced gastric cancer
S‐1 showed no clear difference in treatment‐related deaths compared with 5‐FU‐containing regimens (moderate certainty).
1 finding from 1 review
Treatment discontinuation due to toxicity · people with advanced gastric cancer
S‐1 showed no clear difference in treatment discontinuation due to toxicity compared with 5‐FU‐containing regimens (high certainty).
1 finding from 1 review
Overall survival · people with advanced gastric cancer
5‐FU/cisplatin/anthracycline combinations probably leads to lower overall survival compared with 5‐FU/cisplatin combinations (without anthracyclines) (moderate certainty).
1 finding from 1 review
Tumour response · people with advanced gastric cancer
5‐FU/cisplatin/anthracycline combinations may leads to higher tumour response compared with 5‐FU/cisplatin combinations (without anthracyclines) (low certainty).
1 finding from 1 review
Time to progression · people with advanced gastric cancer
5‐FU/cisplatin/anthracycline combinations may leads to lower time to progression compared with 5‐FU/cisplatin combinations (without anthracyclines) (low certainty).
1 finding from 1 review
Odds of reversion · patients with supraventricular tachycardia
1 finding from 1 review
no estimate extracted
622 participants
Moderate
Major adverse event: hypotension · patients with supraventricular tachycardia
1 finding from 1 review
no estimate extracted
306 participants
Low
Length of hospital stay · patients with supraventricular tachycardia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Patient satisfaction · patients with supraventricular tachycardia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · paediatric patients following heart surgery
Prophylactic levosimendan showed no clear difference in mortality compared with standard treatment (low certainty).
1 finding from 1 review
Low cardiac output syndrome (LCOS) · paediatric patients following heart surgery
Prophylactic levosimendan showed no clear difference in low cardiac output syndrome (LCOS) compared with standard treatment (low certainty).
1 finding from 1 review
Duration of ICU stay · paediatric patients following heart surgery
1 finding from 1 review
Length of hospital stay · paediatric patients following heart surgery
1 finding from 1 review
Duration of mechanical ventilation · paediatric patients following heart surgery
1 finding from 1 review
Mechanical circulatory support or cardiac transplantation · paediatric patients following heart surgery
Prophylactic levosimendan showed no clear difference in mechanical circulatory support or cardiac transplantation compared with standard treatment (low certainty).
1 finding from 1 review
Intervention not reported
PTB (< 37 w) · women with known obstetric outcomes
It is very uncertain whether the intervention changes PTB (< 37 w) (very low certainty).
1 finding from 1 review
Intervention not reported
LBW (< 2500 g) ‐ Treatment versus No Treatment · women with known obstetric outcomes
It is very uncertain whether the intervention changes LBW (< 2500 g) ‐ Treatment versus No Treatment (very low certainty).
1 finding from 1 review
Intervention not reported
NICU Admission ‐ Treatment versus No Treatment · women with known obstetric outcomes
The intervention may leads to higher NICU Admission ‐ Treatment versus No Treatment (low certainty).
1 finding from 1 review
Intervention not reported
Perinatal Mortality ‐ Treatment versus No Treatment · women with known obstetric outcomes
The intervention may leads to higher perinatal Mortality ‐ Treatment versus No Treatment (low certainty).
1 finding from 1 review
Intervention not reported
PTB (< 32 to 34 w) · women with known obstetric outcomes
It is very uncertain whether the intervention changes PTB (< 32 to 34 w) (very low certainty).
1 finding from 1 review